Envy BP Contains Potentially Dangerous Ingredient, FDA Warns
The Food and Drug Administration (FDA) has released a public notification, warning consumers against a potentially dangerous drug.
The agency is discouraging the use of Envy BP, a product promoted and sold for weight loss. Laboratory analysis confirms that the item contains sibutramine.
Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons. The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This product may also interact, in life-threatening ways, with other medications a consumer may be taking.
The product was sold on various websites, including purelysimpleweightloss.com, and possibly in some retail stores.
The FDA has noted a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals. These products are typically promoted for sexual enhancement, weight loss, and body building and are often represented as being "all natural."
Health care professionals and patients are encouraged to report adverse events or side effects related to the use of this supplement to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.